Articles

When managing type 2 diabetes, most decisions around treatment focus on blood sugar control and cardiovascular outcomes. But what about how patients feel day to day? The diabetes medications quality of life—including side effects like fatigue, gastrointestinal issues, and medication burden—often gets overlooked. Yet, these symptoms directly impact a patient’s …

Treating type 2 diabetes is no longer a one-size-fits-all endeavor. As new therapies emerge, clinicians face the ongoing challenge of selecting and sequencing medications in a way that balances efficacy, safety, cost, and patient preference. This comprehensive guide to type 2 diabetes drug sequencing outlines practical strategies for initiating, intensifying, …

As the demand for GLP‑1 receptor agonists skyrockets, clinics across the country are facing a critical question: How can we maintain quality care without overwhelming our teams? Rising interest in these therapies is placing new pressures on prescribing systems, patient education, and long-term follow-up. This article provides a clear, practical …

Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) are still two of the most dangerous acute complications facing people with diabetes. However, a large portion of these cases can be prevented outside of the hospital. In 2025, the American Diabetes Association (ADA) released expanded guidance focused on DKA outpatient prevention, …

GLP‑1 receptor agonists and dual agonists like tirzepatide have become indispensable in managing type 2 diabetes and obesity. However, their effect on gastric emptying introduces specific risks during surgery that can’t be ignored. As their use grows, the need for clear, coordinated GLP‑1 perioperative management is more important than ever. …

Sleep and diabetes are more connected than ever before. According to the newly released 2025 guidelines, sleep has officially joined nutrition and exercise as a core pillar of cardiometabolic health. Why? Because science shows that poor sleep isn’t just tiring — it can directly impact blood sugar levels, insulin resistance, …

The CKM framework in diabetes care—focusing on cardiovascular, kidney, and metabolic health—is more than a trend. It’s a clinical necessity. The ADA’s 2025 Standards of Care urge clinicians to manage these overlapping risks together, not separately. Why? Because patients with diabetes deserve outcomes that go beyond just A1C. This article …

As diabetes technology evolves at lightning speed, clinics are under increasing pressure to evaluate a growing range of tools—from continuous glucose monitors (CGMs) and insulin pumps to smartphone apps and cloud platforms. But how can healthcare providers make safe, informed decisions about which tools to recommend? A clear, structured diabetes …

Diabetes technology safety has become a critical focus as continuous glucose monitors (CGMs), insulin pumps, and automated insulin delivery systems transform diabetes care. These tools improve glycemic outcomes, enhance quality of life, and support proactive management. However, with increased device complexity comes a unique set of risks clinicians must recognize …

As GLP‑1 drugs become more widely used for managing type 2 diabetes and obesity, concerns about access disparities have intensified. Unequal distribution and affordability threaten to create a two-tier healthcare system—where only those with greater means receive these life-changing therapies. In this article, we explore the concept of GLP‑1 access …